A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
Stephen H. Petersdorf(Fred Hutch Cancer Center), Frederick R. Appelbaum(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Patrick J. Stiff(Loyola University Medical Center), Roland B. Walter(Rafael Advanced Defense Systems (Israel)), Robert K. Stuart(Memorial Sloan Kettering Cancer Center), Joseph Brandwein(Goethe University Frankfurt), Thomas J. Nevill(Leukemia & Lymphoma Society of Canada), Martin S. Tallman(Memorial Sloan Kettering Cancer Center), Cheryl L. Willman(Mayo Clinic), Richard A. Larson(Urbana University), Marilyn L. Slovak(City Of Hope National Medical Center), Kenneth J. Kopecky(City Of Hope National Medical Center), Harry P. Erba(Michigan Center for Translational Pathology), Leif Stenke(Karolinska University Hospital)
Cited by 632
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3k